QVANTIG Trademark

Trademark Overview


On Friday, August 26, 2022, a trademark application was filed for QVANTIG with the United States Patent and Trademark Office. The USPTO has given the QVANTIG trademark a serial number of 97566219. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Thursday, July 25, 2024. This trademark is owned by Bristol-Myers Squibb Company. The QVANTIG trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
qvantig

General Information


Serial Number97566219
Word MarkQVANTIG
Filing DateFriday, August 26, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateThursday, July 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 20, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 14, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Tuesday, August 30, 2022NEW APPLICATION ENTERED
Wednesday, September 14, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 1, 2023ASSIGNED TO EXAMINER
Wednesday, March 8, 2023NON-FINAL ACTION WRITTEN
Wednesday, March 8, 2023NON-FINAL ACTION E-MAILED
Wednesday, March 8, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 16, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 16, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 16, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 31, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 20, 2023PUBLISHED FOR OPPOSITION
Tuesday, June 20, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, January 12, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 12, 2024SOU EXTENSION 1 FILED
Friday, January 12, 2024SOU EXTENSION 1 GRANTED
Tuesday, January 16, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 15, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, July 25, 2024SOU TEAS EXTENSION RECEIVED
Thursday, July 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 25, 2024SOU EXTENSION 2 GRANTED
Thursday, July 25, 2024SOU EXTENSION 2 FILED